Prime Medicine (PRME) Free Cash Flow (2021 - 2026)
Prime Medicine (PRME) posted Free Cash Flow of -$42.7 million for Q1 2026, down 13.75% on a QoQ basis from -$37.5 million in Q4 2025, and up 16.71% year-over-year from -$36.6 million in Q1 2025.
Prime Medicine (PRME) Free Cash Flow (2021 - 2026) Analysis & Trends
Prime Medicine's Free Cash Flow history runs 6 years deep, the most recent figure standing at -$42.7 million for Q1 2026.
- Quarterly Free Cash Flow rose 16.71% year-over-year to -$42.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$158.5 million (down 48.49% YoY) and the FY2025 annual result came in at -$167.1 million, down 34.73% from the prior year.
- Free Cash Flow was -$42.7 million for Q1 2026 at Prime Medicine, down from -$37.5 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $15.2 million in Q4 2024 and bottomed at -$68.5 million in Q1 2024.
- A 5-year average of -$37.7 million and a median of -$39.1 million in 2025 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2024 — Free Cash Flow soared 129.19% — and 2025, when it slumped 346.98%.
- Prime Medicine's Free Cash Flow stood at -$20.4 million in 2022, then sank by 155.26% to -$52.1 million in 2023, then surged by 129.19% to $15.2 million in 2024, then tumbled by 346.98% to -$37.5 million in 2025, then fell by 13.75% to -$42.7 million in 2026.
- Business Quant data shows PRME's Free Cash Flow at -$42.7 million in Q1 2026, -$37.5 million in Q4 2025, and -$39.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.49 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 158.09 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -354.95 Mn |
| 10 | Prime Medicine | 524.20 Mn | 524.20 Mn | - | -42.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -42.71 Mn |
| Mar 31, 2026 | -42.71 Mn |
| Dec 31, 2025 | -37.55 Mn |
| Dec 31, 2025 | -37.55 Mn |
| Sep 30, 2025 | -39.13 Mn |
| Sep 30, 2025 | -39.13 Mn |
| Jun 30, 2025 | -39.14 Mn |
| Jun 30, 2025 | -39.14 Mn |
| Mar 31, 2025 | -51.28 Mn |
| Mar 31, 2025 | -51.28 Mn |
| Dec 31, 2024 | 15.20 Mn |
| Dec 31, 2024 | 15.20 Mn |
| Sep 30, 2024 | -21.80 Mn |
| Sep 30, 2024 | -21.80 Mn |
| Jun 30, 2024 | -48.88 Mn |
| Jun 30, 2024 | -48.88 Mn |
| Mar 31, 2024 | -68.54 Mn |
| Mar 31, 2024 | -68.54 Mn |
| Dec 31, 2023 | -52.08 Mn |
| Dec 31, 2023 | -52.08 Mn |